Avrobio, Inc. (AVRO)
Stock Price:
$17.38 USD
-0.06 (-0.34%)
Updated Jul 9, 2020 12:35 PM EDT - Market open
Key Info
| Market Cap |
626.30M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-81.84M |
| Shares Out |
36.04M |
| EPS (ttm) |
-2.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$17.38 |
| Previous Close |
$17.44 |
| Change ($) |
-0.06 |
| Change (%) |
-0.34% |
| Day's Open |
17.44 |
| Day's Range |
17.13 - 17.84 |
| Day's Volume |
92,004 |
| 52-Week Range |
9.76 - 29.32 |
More Stats
| Market Cap |
626.30M |
| Enterprise Value |
368.60M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
36.04M |
| Float |
29.34M |
| EPS (basic) |
-2.74 |
| EPS (diluted) |
-2.74 |
| FCF / Share |
-2.20 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.96M |
| Short Ratio |
4.95 |
| Short % of Float |
6.39% |
| Beta |
1.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.50 |
| Revenue |
n/a |
| Operating Income |
-84.70M |
| Net Income |
-81.84M |
| Free Cash Flow |
-74.19M |
| Net Cash |
257.70M |
| Net Cash / Share |
7.15 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-27.35% |
| ROE |
-45.05% |
| ROIC |
-12,974.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
7 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$37.12*
(113.58% upside)
Low
13.0
Current: 17.38
High
58.0
Target: 37.12
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -75.81 | -46.24 | -18.39 | -4.63 |
| Net Income | -72.97 | -46.36 | -18.65 | -4.66 |
| Shares Outstanding | 27.43 | 13.44 | 2.24 | 2.04 |
| Earnings Per Share | -2.66 | -3.62 | -8.38 | -2.44 |
| Operating Cash Flow | -67.67 | -37.65 | -16.38 | -3.31 |
| Capital Expenditures | -1.59 | -1.83 | -0.38 | - |
| Free Cash Flow | -69.25 | -39.48 | -16.77 | -3.31 |
| Cash & Equivalents | 187 | 126 | 5.96 | 5.36 |
| Net Cash / Debt | 187 | 126 | 5.96 | 5.36 |
| Assets | 201 | 133 | 7.02 | 5.40 |
| Liabilities | 14.50 | 11.30 | 3.66 | 0.98 |
| Book Value | 186 | 122 | -23.14 | -4.58 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Avrobio, Inc. |
| Country |
United States |
| Employees |
112 |
| CEO |
Geoff MacKay |
Stock Information
| Ticker Symbol |
AVRO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AVRO |
| IPO Date |
June 21, 2018 |
Description
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.